Modulatory effects of sCD14 and LBP on LPS-host cell interactions

Journal of Endotoxin Research

Volumn 11, Issue 4, 2005, Pages 225-229

  Kitchens, Richard L ^a   Thompson, Patricia A ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Infection; Lipopolysaccharide; LPS binding protein; Plasma lipoproteins; Soluble CD14

Indexed keywords

ANTIDOTE; BACTERIUM LIPOPOLYSACCHARIDE; CD14 ANTIGEN; LIPOPOLYSACCHARIDE BINDING PROTEIN; LIPOPROTEIN; PROTEIN MD 2; TOLL LIKE RECEPTOR 4;

ARTICLE; BACTERIAL INFECTION; CELL INTERACTION; CELL SURFACE; CONCENTRATION RESPONSE; DISEASE MODEL; EXTRAVASCULAR FLUID; GRAM NEGATIVE BACTERIUM; HOST CELL; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INNATE IMMUNITY; NONHUMAN; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SEPSIS; SEPTIC SHOCK;

ACUTE-PHASE PROTEINS; ANIMALS; ANTIGENS, CD14; CARRIER PROTEINS; CELL COMMUNICATION; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; IMMUNITY, NATURAL; LIPOPOLYSACCHARIDES; MEMBRANE GLYCOPROTEINS; MODELS, IMMUNOLOGICAL; SOLUBILITY;

NEGIBACTERIA;

EID: 25444474430     PISSN: 09680519     EISSN: None     Source Type: Journal    
DOI: 10.1179/096805105X46565     Document Type: Article

References (43)

1. Hailman E, Vasselon T, Kelley M et al. Stimulation of macrophages and neutrophils by complexes of lipopolysaccharide and soluble CD14. J Immunol 1996; 156: 4384-4390.
2. Frey EA, Miller DS, Jahr TG et al. Soluble CD14 participates in the response of cells to lipopolysaccharide. J Exp Med 1992; 176: 1665-1671.
3. Pugin J, Schürer-Maly C-C, Leturcq D, Moriarty A, Ulevitch RJ, Tobias PS. Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14. Proc Natl Acad Sci USA 1993; 90: 2744-2748.
4. Schütt C, Schilling T, Kruger C. sCD14 prevents endotoxin inducible oxidative burst response of human monocytes. Allerg Immunol (Leipz) 1991; 37: 159-164.
5. Haziot A, Rong G-W, Bazil V, Silver J, Goyert SM. Recombinant soluble CD14 inhibits LPS-induced tumor necrosis factor-α production by cells in whole blood. J Immunol 1994; 152: 5868-5876.
6. Haziot A, Rong GW, Lin XY, Silver J, Goyert SM. Recombinant soluble CD14 prevents mortality in mice treated with endotoxin (lipopolysaccharide). J Immunol 1995; 154: 6529-6532.
7. Kitchens RL, Thompson PA, Viriyakosol S, O'Keefe GE, Munford RS. Plasma CD14 decreases monocyte responses to LPS by transferring cell-bound LPS to plasma lipoproteins. J Clin Invest 2001; 108: 485-493.
8. Kitchens RL, Wolfbauer G, Albers JJ, Munford RS. Plasma lipoproteins promote the release of bacterial lipopolysaccharide from the monocyte cell surface. J Biol Chem 1999; 274: 34116-34122.
9. Hiki N, Berger D, Dentener MA et al. Changes in endotoxin-binding proteins during major elective surgery: important role for soluble CD14 in regulation of biological activity of systemic endotoxin. Clin Diagn Lab Immunol 1999; 6: 844-850.
10. Landmann R, Zimmerli W, Sansano S et al. Increased circulating soluble CD14 is associated with high mortality in Gram-negative septic shock. J Infect Dis 1995; 171: 639-644.
11. Landmann R, Reber AM, Sansano S, Zimmerli W. Function of soluble CD14 in serum from patients with septic shock. J Infect Dis 1996; 173: 661-668.
12. Burgmann H, Winkler S, Locker GJ et al. Increased serum concentration of soluble CD14 is a prognostic marker in Gram-positive sepsis. Clin Immunol Immunopathol 1996; 80: 307-310.
13. Stelter F, Witt S, Fürll B, Jack RS, Hartung T, Schütt C. Different efficacy of soluble CD14 treatment in high- and low-dose LPS models. Eur J Clin Invest 1998; 28: 205-213.
14. Shuto Y, Kataoka M, Higuchi Y, Matsuura K, Hijiya N, Yamamoto S. Roles of CD14 in LPS-induced liver injury and lethality in mice pretreated with Propionibacterium acnes. Immunol Lett 2004; 94: 47-55.
15. Tamura Y, Higuchi Y, Kataoka M, Akizuki S, Matsuura K, Yamamoto S. CD14 transgenic mice expressing membrane and soluble forms: comparisons of levels of cytokines and lethalities in response to lipopolysaccharide between transgenic and non-transgenic mice. Int Immunol 1999; 11: 333-339.
16. Fong Y, Marano MA, Moldawer LL et al. The acute splanchnic and peripheral tissue metabolic response to endotoxin in humans. J Clin Invest 1990; 85: 1896-1904.
17. Scoazec JY, Feldmann G. In situ immunophenotyping study of endothelial cells of the human hepatic sinusoid: results and functional implications. Hepatology 1991; 14: 789-797.
18. Knolle PA, Löser E, Protzer U et al. Regulation of endotoxin-induced IL-6 production in liver sinusoidal endothelial cells and Kupffer cells by IL-10. Clin Exp Immunol 1997; 107: 555-561.
19. Knolle PA, Gerken G. Local control of the immune response in the liver. Immunol Rev 2000; 174: 21-34.
20. Cauwels A, Frei K, Sansano S et al. The origin and function of soluble CD14 in experimental bacterial meningitis. J Immunol 1999; 162: 4762-4772.
21. Lee JW, Paape MJ, Elsasser TH, Zhao X. Recombinant soluble CD14 reduces severity of intramammary infection by Escherichia coli. Infect Immun 2003; 71: 4034-4039.
22. Schiff DE, Kline L, Soldau K et al. Phagocytosis of Gram-negative bacteria by a unique CD14-dependent mechanism. J Leukoc Biol 1997; 62: 786-794.
23. Vesy CJ, Kitchens RL, Wolfbauer G, Albers JJ, Munford RS. LPS binding protein and phospholipid transfer protein release lipopolysaccharides from Gram-negative bacterial membranes. Infect Immun 1999; 68: 2410-2417.
24. Hailman E, Lichenstein HS, Wurfel MM et al. Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14. J Exp Med 1994; 179: 269-277.
25. Gegner JA, Ulevitch RJ, Tobias PS. Lipopolysaccharide (LPS) signal transduction and clearance. Dual roles for LPS binding protein and membrane CD14. J Biol Chem 1995; 270: 5320-5326.
26. Dunzendorfer S, Lee HK, Soldau K, Tobias PS. TLR4 is the signaling but not the lipopolysaccharide uptake receptor. J Immunol 2004; 173: 1166-1170.
27. Jack RS, Fan X, Bernhelden M et al. Lipopolysaccharide-binding protein is required to combat a murine Gram-negative bacterial infection. Nature 1997; 389: 742-744.
28. Yang KK, Dorner BG, Merkel U et al. Neutrophil influx in response to a peritoneal infection with Salmonella is delayed in lipopolysaccharide-binding protein or CD14-deficient mice. J Immunol 2002; 169: 4475-4480.
29. Knapp S, de Vos AF, Florquin S, Golenbock DT, van der Poll T. Lipopolysaccharide binding protein is an essential component of the innate immune response to Escherichia coli peritonitis in mice. Infect Immun 2003; 71: 6747-6753.
30. Fan MH, Klein RD, Steinstraesser L et al. An essential role for lipopolysaccharide-binding protein in pulmonary innate immune responses. Shock 2002; 18: 248-254.
31. Heumann D, Lauener R, Ryffel B. The dual role of LBP and CD14 in response to Gram-negative bacteria or Gram-negative compounds. J Endotoxin Res 2003; 9: 381-384.
32. Weber JR, Freyer D, Alexander C et al. Recognition of pneumococcal peptidoglycan: an expanded, pivotal role for LPS binding protein. Immunity 2003; 19: 269-279.
33. Branger J, Florquin S, Knapp S et al. LPS-binding protein-deficient mice have an impaired defense against Gram-negative but not Gram-positive pneumonia. Int Immunol 2004; 16: 1605-1611.
34. Echtenacher B, Freudenberg MA, Jack RS, Mannel DN. Differences in innate defense mechanisms in endotoxemia and polymicrobial septic peritonitis. Infect Immun 2001; 69: 7271-7276.
35. Lamping N, Dettmer R, Schröder NW et al. LPS-binding protein protects mice from septic shock caused by LPS or Gram-negative bacteria. J Clin Invest 1998; 101: 2065-2071.
36. Zweigner J, Gramm HJ, Singer OC, Wegscheider K, Schumann RR. High concentrations of lipopolysaccharide-binding protein in serum of patients with severe sepsis or septic shock inhibit the lipopolysaccharide response in human monocytes. Blood 2001; 98: 3800-3808.
37. Martin TR, Mathison JC, Tobias PS et al. Lipopolysaccharide binding protein enhances the responsiveness of alveolar macrophages to bacterial lipopolysaccharide. Implications for cytokine production in normal and injured lungs. J Clin Invest 1992; 90: 2209-2219.
38. Vreugdenhil ACE, Snoek AMP, Greve JW, Buurman WA. Lipopolysaccharide-binding protein is vectorially secreted and transported by cultured intestinal epithelial cells and is present in the intestinal mucus of mice. J Immunol 2000; 165: 4561-4566.
39. Bannerman DD, Paape MJ, Hare WR, Sohn EJ. Increased levels of LPS-binding protein in bovine blood and milk following bacterial lipopolysaccharide challenge. J Dairy Sci 2003; 86: 3128-3137.
40. Wurfel MM, Kunitake ST, Lichenstein H, Kane JP, Wright SD. Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J Exp Med 1994; 180: 1025-1035.
41. Kitchens RL, Thompson PA, Munford RS, O'Keefe GE. Acute inflammation and infection maintain circulating phospholipid levels and enhance lipopolysaccharide binding to plasma lipoproteins. J Lipid Res 2003; 44: 2339-2348.
42. Gioannini TL, Teghanemt A, Zarember KA, Weiss JP. Regulation of interactions of endotoxin with host cells. J Endotoxin Res 2003; 9: 401-408.
43. Thompson PA, Tobias PS, Viriyakosol S, Kirkland TN, Kitchens RL. Lipopolysaccharide (LPS)-binding protein inhibits responses to cell-bound LPS. J Biol Chem 2003; 278: 28367-28371.